DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Company's Melanoma Advisory Board
"We are delighted and honored to welcome Dr. Halpern to our MelanomaAdvisory Board," said George Schwartz, CEO, DermTech. "Dr. Halpern is a worldleader in the area of melanoma and strategies for improved diagnosis andprevention of this disease that, if identified early, has an extremely highcure rate. DermTech will clearly benefit from his significant experience aswe move toward clinical trials of our novel, non-invasive molecular diagnosticproduct for melanoma early detection."
"I am looking forward to working with the company and the outstandingpanel of dermatologists and melanoma experts already on this advisory board,"said Allan Halpern, MD. Other Melanoma Advisory Board members include: BorisBastian, MD, David Polsky, MD, PhD, and Harold S. Rabinovitz, MD.
Allan Halpern, MD, is a board-certified internist and dermatologist. Inaddition to his role as Chief of Dermatology at MSKCC, he is co-leader of theCenter's Melanoma Disease Management Team, which incorporates the expertise ofdoctors in surgery, medical oncology, clinical immunology, dermatology,pathology, and radiation oncology to diagnose and treat melanoma. Hepioneered the use of digital whole-body photography to assist in the detectionof changing moles in patients with dysplastic nevi (large, irregular coloredor shaped moles). Currently, his research is focused on epidemiologic(population-based) studies with a subset of this research devoted to the studyof the genetic and environmental factors that influence the development ofmoles in children and adolescents. Dr. Halpern received his medical degreefrom the Albert Einstein College of Medicine in New York and completed hisDermatology residency at the Hospital of the University of Pennsylvania. Hehas presented and published extensively on melanoma detection.
Headquartered in La Jolla, California, DermTech International is focusedon the development and validation of molecular tests using specimens obtainedfrom the skin. The company's proprietary Epidermal Genetic InformationRetrieval (EGIR(TM)) technology is in clinical studies to evaluate itspotential as a non-invasive diagnostic for melanoma and other major diseases.It is also being studied in the context of tracking treatment efficacy for avariety of dermatologic and other conditions, including the effects of drugson skin at the molecular level in advance of observable clinical results.DermTech is actively pursuing research using EGIR(TM) and its applications inthe areas of melanoma, prostate cancer and various skin disorders, such aspsoriasis. For additional information visit www.dermtech.com.Contacts: DermTech George Schwartz CEO 858.450.4222 For DermTech Jennifer Larson 415.409.2729 firstname.lastname@example.org
You May Also Like